201 related articles for article (PubMed ID: 18812473)
1. Trisomy 21 enhances human fetal erythro-megakaryocytic development.
Chou ST; Opalinska JB; Yao Y; Fernandes MA; Kalota A; Brooks JS; Choi JK; Gewirtz AM; Danet-Desnoyers GA; Nemiroff RL; Weiss MJ
Blood; 2008 Dec; 112(12):4503-6. PubMed ID: 18812473
[TBL] [Abstract][Full Text] [Related]
2. Morphologic and GATA1 sequencing analysis of hematopoiesis in fetuses with trisomy 21.
Hoeller S; Bihl MP; Tzankov A; Chaffard R; Hirschmann P; Miny P; Kühne T; Bruder E
Hum Pathol; 2014 May; 45(5):1003-9. PubMed ID: 24746204
[TBL] [Abstract][Full Text] [Related]
3. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
[TBL] [Abstract][Full Text] [Related]
4. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
[TBL] [Abstract][Full Text] [Related]
5. Early lineage priming by trisomy of Erg leads to myeloproliferation in a Down syndrome model.
Ng AP; Hu Y; Metcalf D; Hyland CD; Ierino H; Phipson B; Wu D; Baldwin TM; Kauppi M; Kiu H; Di Rago L; Hilton DJ; Smyth GK; Alexander WS
PLoS Genet; 2015 May; 11(5):e1005211. PubMed ID: 25973911
[TBL] [Abstract][Full Text] [Related]
6. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
Vyas P; Roberts I
Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
[TBL] [Abstract][Full Text] [Related]
7. Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder.
Birger Y; Goldberg L; Chlon TM; Goldenson B; Muler I; Schiby G; Jacob-Hirsch J; Rechavi G; Crispino JD; Izraeli S
Blood; 2013 Aug; 122(6):988-98. PubMed ID: 23719302
[TBL] [Abstract][Full Text] [Related]
8. GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome.
Garnett C; Cruz Hernandez D; Vyas P
IUBMB Life; 2020 Jan; 72(1):119-130. PubMed ID: 31769932
[TBL] [Abstract][Full Text] [Related]
9. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
[TBL] [Abstract][Full Text] [Related]
10. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.
Li Z; Godinho FJ; Klusmann JH; Garriga-Canut M; Yu C; Orkin SH
Nat Genet; 2005 Jun; 37(6):613-9. PubMed ID: 15895080
[TBL] [Abstract][Full Text] [Related]
11. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
[TBL] [Abstract][Full Text] [Related]
12. Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations.
Tunstall-Pedoe O; Roy A; Karadimitris A; de la Fuente J; Fisk NM; Bennett P; Norton A; Vyas P; Roberts I
Blood; 2008 Dec; 112(12):4507-11. PubMed ID: 18689547
[TBL] [Abstract][Full Text] [Related]
13. The abundance of the short GATA1 isoform affects megakaryocyte differentiation and leukemic predisposition in mice.
Ishihara D; Hasegawa A; Hirano I; Engel JD; Yamamoto M; Shimizu R
Exp Hematol Oncol; 2024 Feb; 13(1):24. PubMed ID: 38409186
[TBL] [Abstract][Full Text] [Related]
14. Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome.
Ito E; Kasai M; Hayashi Y; Toki T; Arai K; Yokoyama S; Kato K; Tachibana N; Yamamoto M; Yokoyama M
Br J Haematol; 1995 Jul; 90(3):607-14. PubMed ID: 7647001
[TBL] [Abstract][Full Text] [Related]
15. Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant.
Shimizu R; Kobayashi E; Engel JD; Yamamoto M
Genes Cells; 2009 Sep; 14(9):1119-31. PubMed ID: 19682090
[TBL] [Abstract][Full Text] [Related]
16. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
17. Expression of erythroid-specific genes in megakaryoblastic disorders.
Ito E; Kasai M; Toki T; Arai K; Yokoyama M
Leuk Lymphoma; 1996 Nov; 23(5-6):545-50. PubMed ID: 9031085
[TBL] [Abstract][Full Text] [Related]
18. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
Roy A; Roberts I; Norton A; Vyas P
Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
[TBL] [Abstract][Full Text] [Related]
19. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.
Hitzler JK; Cheung J; Li Y; Scherer SW; Zipursky A
Blood; 2003 Jun; 101(11):4301-4. PubMed ID: 12586620
[TBL] [Abstract][Full Text] [Related]
20. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome.
Xu G; Nagano M; Kanezaki R; Toki T; Hayashi Y; Taketani T; Taki T; Mitui T; Koike K; Kato K; Imaizumi M; Sekine I; Ikeda Y; Hanada R; Sako M; Kudo K; Kojima S; Ohneda O; Yamamoto M; Ito E
Blood; 2003 Oct; 102(8):2960-8. PubMed ID: 12816863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
